How does the Aegis Antimicrobial
The AEGIS Microbe Shield is a reactive saline quaternary ammonium
compound. When applied as a liquid to a host filter material the active
ingredient in the AEGIS Antimicrobial forms a colorless, odorless,
positively charge polymer coating which chemically bonds, virtually
irremovable, to the treated surface. You could think of it as a layer of
electrically charged swords. When a microorganism come in contact with
the treated surface, the sword punctures the cell membrane and the
electrical charge shocks the cell. Since nothing is transferred to the
now dead cell, the Antimicrobial doesn’t lose strength the sword is
ready for the next cell to contact it.
What are the differences between the AEGIS Microbe shield
technology and other Antimicrobials on the market?
Conventional Antimicrobial products penetrate livings cells and kill by
way of poisoning the organism. This poisoning technology is applied to a
host media where it slowly leaches out creating a "killing field or
zone" around the surface into which targeted microorganisms pass. They
are designed to act quickly and dissipate quickly in order to avoid
adverse effects to humans and animals due to their toxic ingredients.
The AEGIS Antimicrobial takes a totally unique approach. It provides an
effective initial microbial kill when applied, like the conventional
methods, but it also provides long-term control of growth on treated
surfaces for the life of that surface. The surface itself is modified to
make it anti-microbial active.
Is the AEGIS Microbe Shield Toxic?
No. Unlike all other conventional antimicrobials, AEGIS does not off
gas, leach, diffuse, migrate, volatilize, or otherwise leave the surface
to which it has been applied. The result is an extraordinary safety and
efficacy profile unmatched by other products. The incorporation of AEGIS
Antimicrobial, and its remarkable surface modifying characteristics, has
produced a new generation of air filtration products that can provide
effective control of airborne microbes while eliminating the filter
surface as a potential site for bacteria growth.
Commercialization of Dow Corning’s anti-microbial technology began in
1976 after receiving EPA registration under what are called "modern"
standards of review. Years of research by Burlington Industries, outside
laboratories and Dow Corning verified the safety and utility of direct
human contact with this technology. American Hospital Supply Corporation
(now part of Baxter International) was reviewing the use of
antimicrobials on medical non-woven products. The stringent rules
governing the use of any particulates or chemicals that could enter the
body via a wound, etc. made this review protocol very severe. Every
available antimicrobial, medical and industrial, was screened for basic
toxicity, effectiveness against the types of microorganisms encountered
in surgery and compatibility with the variety of physical, chemical, and
biological contaminants found on fabrics and in wounds, but most
importantly, the agents durability to leaching (the consequences of
contamination into a wound area can be profound). This research
eliminated all other antimicrobials except what is known today as the
ÆGIS Antimicrobial. American Hospital Supply Corporation, outside
university laboratories, private laboratories and Dow Corning
contributed over thirty (30) studies verifying the safety and
performance of this technology in medical use. FDA listings were
obtained and ISO-BAC Medical Nonwovens were introduced to the market.
After its release, Dow immediately started research and development
programs, and after testing and reviewing all available antimicrobials,
their technical assessment was unquestionable in its verification of the
utility of the Dow Corning, now AEGIS® Antimicrobial over any other